TrialJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2023

MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.

Kai He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.